secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2024-11-20T23:59:59+00:00
Accession:  0001437749-24-035812
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex enters exclusive license with Univ of Michigan for Reqorsa in ALK+ lung cancer
--------------------------------------------------------------------------------

- License grants Genprex worldwide exclusive rights to University of Michigan patents for Reqorsa gene therapy combined with ALK-inhibitors for ALK-EML4 positive NSCLC.
- Preclinical data at AACR April 2024 showed Reqorsa induced apoptosis in alectinib-resistant EML4-ALK positive NSCLC cell lines.
- Researchers believe results support further clinical study of Reqorsa as an anti-ALK NSCLC treatment strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/0001437749-24-035812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774924035812/gnpx20241119_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer